Cargando…
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy
In this study, we investigated the metabolic alterations associated with clinical response to chemotherapy in patients with ovarian cancer. Pre- and post-neoadjuvant chemotherapy (NACT) tissues from patients with high-grade serous ovarian cancer (HGSC) who had poor response (PR) or excellent respons...
Autores principales: | Corvigno, Sara, Badal, Sunil, Spradlin, Meredith L., Keating, Michael, Pereira, Igor, Stur, Elaine, Bayraktar, Emine, Foster, Katherine I., Bateman, Nicholas W., Barakat, Waleed, Darcy, Kathleen M., Conrads, Thomas P., Maxwell, G. Larry, Lorenzi, Philip L., Lutgendorf, Susan K., Wen, Yunfei, Zhao, Li, Thaker, Premal H., Goodheart, Michael J., Liu, Jinsong, Fleming, Nicole, Lee, Sanghoon, Eberlin, Livia S., Sood, Anil K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624842/ https://www.ncbi.nlm.nih.gov/pubmed/37923835 http://dx.doi.org/10.1038/s41698-023-00454-0 |
Ejemplares similares
-
Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022) -
Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma
por: Stur, Elaine, et al.
Publicado: (2022) -
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer
por: Glassman, Deanna, et al.
Publicado: (2023) -
Diurnal Cortisol and Survival in Epithelial Ovarian Cancer
por: Schrepf, Andrew, et al.
Publicado: (2015) -
Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
por: Wu, Yutuan, et al.
Publicado: (2022)